Twist Bioscience Collaborates with Deep Learning Experts deepCDR on Antibody Library Design
September 23 2021 - 7:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced a collaboration
with deepCDR, a private company focused on applying deep learning
algorithms to antibody discovery and optimization.
“We continue to leverage and integrate cutting-edge technologies
that advance our antibody discovery and optimization capabilities,
and deepCDR offers a unique approach enabled by deep learning to
generate large panels of fully human antibody sequences. Utilizing
these sequences, we’ve built multiple fully human naïve synthetic
antibody libraries – specifically AI Hypermutated single-chain
fragment variable (scFv) library and a new coronavirus specific
scFv library – to add to our ever-growing Library of Libraries,”
said Emily M. Leproust, Ph.D., CEO and co-founder of Twist
Bioscience.
“Twist has deep and broad expertise in designing and
synthesizing very large antibody libraries as well as optimizing
potential antibodies to improve their biochemical properties. We
then apply our deep learning algorithms to decrease the downstream
validation work necessary for preclinical development. It’s a
productive and complementary collaboration for both organizations,”
commented Sai Reddy, Ph.D., founder and scientific advisor to
deepCDR.
About deepCDR Biologics (Basel, Switzerland)
deepCDR uses unique deep learning methods combined with its
proprietary mammalian display platform to select from a massively
wide range of antibodies and rapidly identify candidates with the
highest possible affinity and developability profiles.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn |
YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including the ability of the collaboration with deepCDR to
reduce downstream preclinical development validation work related
to antibodies, are forward-looking statements reflecting the
current beliefs and expectations of management made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements involve known and
unknown risks, uncertainties, and other important factors that may
cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risks and uncertainties of the ability to attract
new customers and retain and grow sales from existing customers;
risks and uncertainties of rapidly changing technologies and
extensive competition in synthetic biology could make the products
Twist Bioscience is developing obsolete or non-competitive; the
retention of employees of acquired companies and the ability of
Twist Bioscience to successfully integrate acquired companies and
to achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2021, and subsequent filings with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210923005236/en/
For Twist Bioscience Angela Bitting SVP, Corporate
Affairs 925- 202-6211 media@twistbioscience.com
For deepCDR: Simon Friedensohn, PhD Director of R&D
info@deepcdr.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024